Australian Primary Health Care Research Institute, Australian National University, Canberra, Australian Capital Territory, Australia.
The Centre for Research and Action in Public Health (CeRAPH), University of Canberra, Canberra, Australian Capital Territory, Australia.
Intern Med J. 2016 Aug;46(8):955-63. doi: 10.1111/imj.12966.
Opioid prescribing/dispensing data can inform policy surrounding regulation by informing trends and types of opioid prescribed and geographic variations. In Australia so far only partial data on dispensing have been published, and data for states/territories remain unknown.
Using a range of measures, this study examines 20-year (1992-2011) trends in prescription opioid analgesics in Australia - both nationally and for individual jurisdictions.
Dispensing data were obtained from the Drug Utilisation Sub-Committee and the Pharmaceutical Benefits Scheme (PBS) websites. Trends in numbers of prescriptions and daily defined dose (DDD)/1000 people/day were examined over time and across states/territories. Seasonal variations in PBS/Repatriation Pharmaceutical Benefits Scheme (RPBS) items for nationwide dispensing were adjusted using a centred moving smoothing technique.
In two decades, 165.32 million prescriptions for opioids were dispensed, with codeine and its derivatives the most prescribed formulation (50.1%) followed by tramadol (13.5%) and oxycodone derivatives (12.7%). In terms of DDD/1000 people/day, dispensing increased from 5.38 in 1992 to 14.46 in 2011. There are significant increasing trends for total, PBS/RPBS and under co-payment prescriptions (priced below patient co-payment). The DDD/1000 people/day for items dispensed through PBS/RPBS was highest in Tasmania.
Prescription opioid dispensing increased substantially over the study period. With an ageing population, this trend is likely to continue in future. A growing concern about harms associated with opioid use warrants balanced control measures so that harms could be minimised without reducing effective pain treatment. Research examining utilisation in small geographic areas may help design spatially tailored interventions. A real-time drug-monitoring programme may reduce undue prescribing and dispensing.
阿片类药物的处方/配药数据可以通过提供处方阿片类药物的趋势和类型以及地域差异,为监管政策提供信息。到目前为止,澳大利亚只公布了部分关于配药的数据,而各州/地区的数据仍不清楚。
本研究使用多种指标,考察了澳大利亚 20 年来(1992-2011 年)处方类阿片类镇痛药的情况,包括全国和各司法管辖区的情况。
从药物利用小组委员会和药品福利计划(PBS)网站获取配药数据。考察了一段时间内和各州/地区之间处方数量和每日规定剂量(DDD)/每千人/天的趋势。使用中心化移动平滑技术调整全国范围内 PBS/退伍军人药品福利计划(RPBS)配药的季节性变化。
在二十年中,开出了 1.6532 亿张阿片类药物处方,其中最常开的剂型是可待因及其衍生物(50.1%),其次是曲马多(13.5%)和羟考酮衍生物(12.7%)。按 DDD/1000 人/天计算,配药量从 1992 年的 5.38 增加到 2011 年的 14.46。总处方、PBS/RPBS 和自费处方(低于患者自费标准)的配药量呈显著上升趋势。通过 PBS/RPBS 配药的 DDD/1000 人/天在塔斯马尼亚最高。
在研究期间,阿片类药物的处方配药量大幅增加。随着人口老龄化,这一趋势在未来可能会继续。人们越来越关注与阿片类药物使用相关的危害,这需要采取平衡的控制措施,以便在不减少有效止痛治疗的情况下将危害降到最低。研究小范围地域利用情况的研究可能有助于设计有针对性的干预措施。实时药物监测计划可能会减少不必要的处方和配药。